Program
Goserelin
Also written as “Goserelin acetate”, “ZOLADEX” and “Inj. Goserelin (Test) Subcutaneously”.
Its studies are mostly in Breast Neoplasms · Prostatic Neoplasms · Metrorrhagia, led by 4 companies.
Drug pageGoserelin: every studyAll 103 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 80 open or running | phase 4since Oct 26, 2005 | Oct 10, 2005 | none ahead |
| Eurofarma Laboratoriosits history only | 20 open or running | phase 3since Apr 29, 2019 | Apr 29, 2019 | none ahead |
| Peptigroupe | 10 open or running | phase 1since Jun 9, 2020 | Jun 9, 2020 | none ahead |
| TerSera Therapeuticsits history only | 11 open or running | phase 1since Dec 16, 2025 | Dec 16, 2025 | Mar 30, 2027phase 1 · NCT07310420 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Peptigroupe only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 9, 2020First study: phase 1 study in MetrorrhagiaFirst studyNCT04428684 · 80 enrolled · Ukraine
TargetBeta
“A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity”NCIt, by rule
“Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| triptorelinrule | Ipsen | phase 4 | 21 |
Studies
The one study Peptigroupe leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04428684Metrorrhagia · Ukraine | 1 | Completed | Apr 1, 2020 | 80 |
How it is read
Names in the registry
- “Goserelin acetate”, 5 entries
- “Goserelin”, 2 entries
- “ZOLADEX”, 1 entry
- “Inj. Goserelin (Test) Subcutaneously”, 1 entry
- “Goserelin acetate 3.6 mg Injection”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 10 studies
- Prostatic Neoplasms, 3 studies
- Metrorrhagia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.